The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Osteoporosis Drugs Tied to Lower Fracture Risk & Health Costs

Osteoporosis Drugs Tied to Lower Fracture Risk & Health Costs

August 13, 2018 • By Lisa Rapaport

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—Older women with osteoporosis who consistently take a bisphosphonate may have a lower risk of fractures and lower total health costs than their counterparts who stop taking these drugs, a U.S. study suggests.

You Might Also Like
  • After Hip Fracture, Earlier Osteoporosis Drug Initiation Tied to Lower Subsequent Fracture Risk
  • Mediterranean Diet Tied to Lower Hip Fracture Risk
  • Serum Bone Markers CTX, PINP Not Linked with Hip Fracture Risk in Osteoporosis

Researchers examined data on 294,369 women who were at least 66 years old, insured by Medicare and prescribed osteoporosis medicines for the first time at some point between 2009 and 2011.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Overall, roughly one third of these women consistently took their medications for at least a year with no gaps of two months or longer. The remaining two-thirds were considered “non-persistent” users because they had even longer lapses in medication use.

Among women who consistently took their drugs, annual fracture rates dropped from 16.2 fractures for every 100 patients in the six months before starting medication to 4.1 fractures for every 100 patients in the first 18 months of using osteoporosis drugs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Women who were non-persistent users, however, had higher annual fracture rates: 19 fractures for every 100 patients in the six months before starting medication, and 7.3 fractures for every 100 patients over the first 18 months after drugs were prescribed.

“Osteoporosis medications can increase bone formation or decrease bone break down, resulting in increased bone density, therefore, decreased risk of fracture,” says lead study author Jiannong Liu, PhD, of the Hennepin Healthcare Research Institute in Minneapolis.

“When the medication stops, bone density will decrease again,” Dr. Liu says by email.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Widespread use of bisphosphonates in the U.S. coincided with a dramatic decline in fractures from the mid-1990s to the mid-2000s. But use of these medicines has declined in recent years following reports of rare, but serious side effects including unusual fractures of the thighbone, death of bone tissue in the jaw and esophageal cancer.

More than one-third of women prescribed bisphosphonates never fill their first prescription, researchers note in Osteoporosis International, online July 18.1

In the study, about nine in 10 women who didn’t consistently take their medicines stopped refilling their prescriptions.

Total average health costs for patients who didn’t take medicines as prescribed were $19,181 a year, compared with $14,476 for women who consistently took their drugs.

Fracture-related costs were higher without consistent medication use, averaging $641 a year compared with $292 for women who stuck with their medicines.

Without consistent drug use, women also had higher inpatient hospital costs: an average of $6,297 compared with $3,516 for those who did take the medicines.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: Bisphosphonate, fracture risk, Fractures, Osteoporosis, osteoporosis treatments

You Might Also Like:
  • After Hip Fracture, Earlier Osteoporosis Drug Initiation Tied to Lower Subsequent Fracture Risk
  • Mediterranean Diet Tied to Lower Hip Fracture Risk
  • Serum Bone Markers CTX, PINP Not Linked with Hip Fracture Risk in Osteoporosis
  • Vitamin D, Calcium Supplements May Not Lower Fracture Risk

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.